DBV Technologies Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $90.5M

Website

Clinical Trials

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

Phase 3

Active, not recruiting

Conditions: Allergy, Peanut

Interventions: Drug: DBV712
Other: Placebo

First Posted Date: 2023-02-23

Last Posted Date: 2024-12-04

Lead Sponsor: DBV Technologies

Target Recruit Count: 600

Registration Number: NCT05741476

Locations: 🇬🇧
DBV Investigative Site, Southampton, United Kingdom
🇺🇸
DBV Investigative site, Atlanta, Georgia, United States

Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children

Conditions: Peanut Allergy

First Posted Date: 2022-06-21

Last Posted Date: 2023-03-06

Lead Sponsor: DBV Technologies

Registration Number: NCT05424731

Locations: 🇺🇸
Early Access Care, LLC, Madison, Connecticut, United States

Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children

Phase 2

Conditions: Cow's Milk Allergy

Interventions: Combination Product: DBV1605

First Posted Date: 2020-07-30

Last Posted Date: 2022-08-11

Lead Sponsor: DBV Technologies

Target Recruit Count: 230

Registration Number: NCT04492683

Locations: 🇨🇦
Hamilton Allergy, Hamilton, Ontario, Canada
🇮🇹
Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
🇺🇸
Allergy Center at Brookstone - Research Department, Columbus, Georgia, United States

and more 30 locations

Viaskin® Peanut (DBV712) Expanded Access Protocol

Conditions: Peanut Allergy

First Posted Date: 2020-05-01

Last Posted Date: 2021-05-28

Lead Sponsor: DBV Technologies

Registration Number: NCT04371627

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Phase 3

Active, not recruiting

Conditions: Peanut Allergy

Interventions: Biological: DBV712 250 mcg

First Posted Date: 2019-03-01

Last Posted Date: 2024-11-19

Lead Sponsor: DBV Technologies

Target Recruit Count: 330

Registration Number: NCT03859700

Locations: 🇺🇸
Banner University Medical Center Tucson, Tucson, Arizona, United States
🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
University of Rochester, Rochester, New York, United States

and more 23 locations

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

Phase 1

Completed

Conditions: Peanut Allergy

Interventions: Drug: DBV712 IHRP

First Posted Date: 2017-11-24

Last Posted Date: 2019-07-26

Lead Sponsor: DBV Technologies

Target Recruit Count: 27

Registration Number: NCT03352726

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

Phase 3

Completed

Conditions: Peanut Allergy

Interventions: Biological: Part A Viaskin Peanut 250 mcg
Biological: Part A Viaskin Peanut 100 mcg
Biological: Part A Placebo
Biological: Part B Viaskin Peanut 250 mcg
Biological: Part B Placebo

First Posted Date: 2017-07-07

Last Posted Date: 2024-12-16

Lead Sponsor: DBV Technologies

Target Recruit Count: 414

Registration Number: NCT03211247

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
University of California School of Medicine, Los Angeles, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 48 locations

Viaskin Pertussis Vaccine Trial

Phase 1

Completed

Conditions: Whooping Cough

Interventions: Biological: Viaskin PT 25 mcg
Biological: Viaskin PT 50 mcg
Biological: Viaskin PT Placebo
Biological: Boostrix™

First Posted Date: 2017-01-30

Last Posted Date: 2020-03-02

Lead Sponsor: DBV Technologies

Target Recruit Count: 102

Registration Number: NCT03035370

Locations: 🇨🇭
Center for Vaccinology Medical faculty UNIGE and University of Geneva (HUG), Geneva, Switzerland

Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

Phase 3

Conditions: Peanut Allergy

Interventions: Drug: Viaskin Peanut 250µg

First Posted Date: 2017-01-06

Last Posted Date: 2020-12-02

Lead Sponsor: DBV Technologies

Target Recruit Count: 300

Registration Number: NCT03013517

Locations: 🇮🇪
Clinical Investigations Unit, Cork, Ireland
🇦🇺
Princess Margaret Hospital for Children, Perth, Australia
🇺🇸
Stanford University School of Medicine, Stanford, California, United States

and more 28 locations

Safety Study of Viaskin Peanut to Treat Peanut Allergy

Phase 3

Completed

Conditions: Peanut Allergy

Interventions: Biological: Viaskin Peanut 250 mcg
Biological: Placebo

First Posted Date: 2016-09-27

Last Posted Date: 2021-02-03

Lead Sponsor: DBV Technologies

Target Recruit Count: 393

Registration Number: NCT02916446

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Palos Verdes Medical Group, Rolling Hills Estates, California, United States

and more 29 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy